Dr. Price has served as NeuroBo’s President and Chief Executive Officer since November 2021. Prior to joining NeuroBo, and since 2017, Dr. Price was Chief Medical Officer of the pharmacovigilance team of ProPharma Group, a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. Previous to that, he served as Chief Executive Officer and Chief Medical Officer of Drug Safety Solutions, Inc., a provider of solutions for clinical and drug safety operations, from 2002 until its acquisition by ProPharma Group in 2017. From 1997 to 2002, Dr. Price was the Director of Clinical Development for Oncology at MedImmune, Inc., which is now the biologics subsidiary of AstraZeneca plc. Prior to joining MedImmune, Dr. Price worked in the contract research organization sector. Dr. Price began his pharmaceutical career at Glaxo Inc., (now GlaxoSmithKline plc) where he worked for nearly nine years in both the commercial and research divisions of that company.
From 2007 to 2016, Dr. Price served on the board of directors of Sarepta Therapeutics, Inc., a publicly traded commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. Dr. Price is a clinical physician trained in internal medicine and is a former member of the American Medical Association, the Academy of Pharmaceutical Physicians and the American Society for Microbiology. Dr. Price received a B.A. from the University of Rio Grande and a M.D. from the University of Santiago.
Mr. Kondrad has served as NeuroBo’s Vice President, Corporate and Business Development since February 2022. He also serves as Managing Partner, Kondrad Consulting Group, LLC., where he has led business strategy projects for biopharmaceutical and medical device companies including business development and licensing support, payer strategy, CMC benchmarking and regulatory readiness, brand commercialization, market research, and as an expert witness supporting litigations within the pharmaceutical industry. Previously, from 1995 to 2017, Mr. Kondrad held positions of increasing responsibility with AstraZeneca including Executive Director Business Development and Licensing, Neuroscience Clinical Program Senior Director, Managed Markets Director, Director of External Medical Relations, NEXIUM® Brand Leader, CRESTOR® Senior Research Manager, International Strategic Planning Manager (based in the UK) and Head of CMC Project Management and Regulatory Documentation. In addition, he held strategic interface roles between key external medical, scientific, policy groups and AstraZeneca on emerging healthcare reform issues.
Mr. Kondrad earned a degree from Philadelphia College of Pharmacy & Science and completed programs in pharmacology, business and leadership from Hahnemann Medical University, Wharton School of Business, INSEAD, and the Center for Creative Leadership. He is an active member of the Licensing Executive Society (LES), Academy of Managed Care Pharmacy (AMCP), European Society of Cardiology (ESC), INTELLUS Worldwide (biopharma market research society) and founding member of the Pharmaceutical Section of the Project Management Institute (PMI).
Mrs. Kondrad has served as NeuroBo’s Vice President, Intellectual Property since February 2022. She also serves as Partner, Kondrad Consulting Group, LLC. Karen is a consulting intellectual property attorney with extensive global industry experience and a broad background in due diligence, agreements, business development, licensing, IP, and managing external counsel. Karen has helped clients and companies with corporate business divestments, IP strategy and investor communications, led IP contract negotiations for multi-billion-dollar acquisitions and divestment of commercial products, late and early-stage R&D assets, and technologies and research collaborations with companies and universities. She has led successful litigation of IPR, EU patent challenges, global patent procurement and prosecution, licensing patent due diligence, and freedom-to-operate determinations.
Karen earned degrees in chemistry from the Philadelphia College of Pharmacy & Science and law from Widener University/Delaware Law School.
Previously, Karen held positions of increasing responsibility at AstraZeneca including Principal Patent Attorney for Business Development and Licensing, at Dupont Pharmaceuticals as Senior Patent Attorney, Chief Trademark Council, and Assistant General Counsel, and at GlaxoSmithKline as Senior Medicinal Chemist.
Karen is licensed and admitted to the Pennsylvania, New Jersey and U.S. Federal Patent Bars and registered for the Delaware Bar’s Rule 55.1. Karen also holds executive leadership roles on several local community boards.